Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT05127148Recruiting
Real-world study of pediatric-like treatment for Ph-negative ALL
This study follows how well a “pediatric-style” treatment plan works in teens and young adults with Ph-negative acute lymphoblastic leukemia (ALL) in real-world care. It mainly aims to understand outcomes and safety for patients who fit the specific leukemia and health criteria.
Paraná, Entre Ríos ProvinceAges 18–40 - NCT05127980Recruiting
Study of immune antibodies after first-time EBV infection
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
BaselAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Duarte, CaliforniaAges 18 years+ - NCT05132179Recruiting
Testing two antiseptic creams for diabetic foot ulcers
This study compares two topical (applied on the skin) antimicrobial agents—Dakin’s and Prontosan—to help heal diabetic foot ulcers. You may be eligible if you have a diabetic foot ulcer that has been present for at least 3 weeks and is large enough.
Uddevalla, TrollhattanAges 18–100 - NCT05136807Recruiting
Quality of life study for people with MGUS or smoldering myeloma
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
Houston, TexasAges 18 years+ - NCT05139706Recruiting
Study immune side effects after cancer immunotherapy
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
Montreal, QuebecAges 18–100 - NCT05139784Recruiting
Study of immune changes in people with type 1 diabetes and other diabetes
This study looks at immune (defense system) and blood-sugar changes in people with type 1 diabetes, and in some other diabetes or autoimmune hormone conditions. It includes people who will have a specific abdominal surgery so doctors can safely study lymph node tissue.
Bobigny, Île-de-France RegionAges 1 year+ - NCT05140889Recruiting
AI helps predict asthma severity in children
This trial studies an AI (computer) model that uses CT scan images plus health and blood/clinical information to predict how severe asthma is in children. It may help doctors better understand your child’s asthma severity and tailor care.
PaviaAges 6–17 - NCT05145361RecruitingEarly Phase 1
Study drug B001 for neuromyelitis optic spectrum disorder attacks
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05145374Recruiting
Testing an insulin pump system for exercise and stress swings
This study tests a smarter (automated) insulin pump approach to help prevent blood sugar problems when you do physical activity or when you’re under sudden stress. It may help people with type 1 diabetes use insulin more safely during real-life changes.
Chicago, IllinoisAges 20–60 - NCT05145400RecruitingPhase 2
Drug treatment for frail or older newly diagnosed multiple myeloma
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
Chapel Hill, North CarolinaAges 18 years+ - NCT05145816RecruitingPhase 1/Phase 2
Belantamab for AL amyloidosis after prior treatments
This study tests belantamab mafodotin, a medicine designed to target amyloid-producing abnormal cells, in people with relapsed or refractory AL (light-chain) amyloidosis. It’s aimed at improving blood and organ-related signs of the disease after earlier treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT05147467RecruitingPhase 2
Trial of APG-2575 for returning or resistant CLL/SLL
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT05147519Recruiting
Observes HIV and other infections to learn who gets them
This is an observational study that follows people to better understand how HIV and other infections (like sexually transmitted infections) happen and change over time. It may help researchers improve prevention and care, but it is mainly for monitoring rather than testing a new treatment.
Kericho, Kericho CountyAges 14–55 - NCT05147688RecruitingPhase 1
Safety study of donor stem cell treatment for lung disease
This early study tests whether donor stem cells made from umbilical cord tissue are safe in people with lung diseases. If you qualify, you may be offered the study treatment while the team closely checks for side effects and safety.
St John'sAges Any age - NCT05152238Recruiting
ITP registry and optional blood sample collection study
This study helps doctors better understand immune thrombocytopenia (ITP) by collecting basic patient information and, if you agree, storing blood samples. It may help future care decisions and research for people with ITP.
AachenAges 18 years+ - NCT05153070RecruitingPhase 2
Cyclosporine then low-dose immune therapy for new type 1 diabetes
This Phase 2 study tests whether starting with cyclosporine and then giving low-dose IL-2 can better protect the body’s insulin-producing function after type 1 diabetes is diagnosed. It’s meant for people diagnosed very recently who have specific diabetes-related immune markers.
ParisAges 16–45 - NCT05153057Recruiting
Follow-up study for birdshot eye inflammation
This study follows people with “birdshot chorioretinopathy,” a rare eye inflammation, and collects immune (genetic) information to better understand the disease. You may benefit from closer monitoring, and the results may help guide future treatments.
Paris, Île-de-France RegionAges 18 years+ - NCT05154370Recruiting
Registry for neuroinflammation diseases and diagnosis categories
This study is a registry that collects information from people diagnosed with certain neuroinflammation conditions. It may help doctors learn how these diseases behave over time and support future research.
Beijing, Beijing MunicipalityAges Any age - NCT05156203RecruitingPhase 1
T-1301 capsules test for advanced solid tumor cancers
This early-phase study tests whether T-1301 capsules are safe and how well they can work in people with advanced solid tumors that can’t be treated with standard options. It focuses on side effects first, but results may help guide future treatment for advanced cancers.
Kaohsiung CityAges 20 years+ - NCT05157685RecruitingPhase 3
Azithromycin for chronic pus-filled sinus inflammation
This Phase 3 trial tests whether the antibiotic azithromycin can improve chronic sinus problems where there is persistent pus and swelling. It’s for adults who have not improved despite at least two prior antibiotics.
BordeauxAges 18–70 - NCT05157581Recruiting
Light-based treatment for Sezary syndrome patients
This trial tests whether a special light treatment done outside the body (extracorporeal photopheresis) can help people with Sezary syndrome. It is meant to see if the treatment is safe and effective for this specific type and stage of skin lymphoma.
Atlanta, GeorgiaAges 18–100 - NCT05159466Recruiting
Transplant from HIV-positive donors to HIV-positive recipients
This trial studies whether it’s safe and effective for HIV-positive people to receive organ transplants from HIV-positive donors. It focuses on matching HIV treatment before and after transplant and checking for major complications.
Metairie, LouisianaAges 18 years+ - NCT05159856Recruiting
Early checks for long-term complications in young type 1 diabetes
This study looks for early signs of long-term complications in children and teens who have type 1 diabetes for more than a year. It may help your clinic spot problems sooner, when treatment could be easier.
Herlev, HerlevAges 6–18
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.